Literature DB >> 20536557

Granzyme A activates another way to die.

Judy Lieberman1.   

Abstract

Granzyme A (GzmA) is the most abundant serine protease in killer cell cytotoxic granules. GzmA activates a novel programed cell death pathway that begins in the mitochondrion, where cleavage of NDUFS3 in electron transport complex I disrupts mitochondrial metabolism and generates reactive oxygen species (ROS). ROS drives the endoplasmic reticulum-associated SET complex into the nucleus, where it activates single-stranded DNA damage. GzmA also targets other important nuclear proteins for degradation, including histones, the lamins that maintain the nuclear envelope, and several key DNA damage repair proteins (Ku70, PARP-1). Cells that are resistant to the caspases or GzmB by overexpressing bcl-2 family anti-apoptotic proteins or caspase or GzmB protease inhibitors are sensitive to GzmA. By activating multiple cell death pathways, killer cells provide better protection against a variety of intracellular pathogens and tumors. GzmA also has proinflammatory activity; it activates pro-interleukin-1beta and may also have other proinflammatory effects that remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536557      PMCID: PMC2905780          DOI: 10.1111/j.0105-2896.2010.00902.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  144 in total

1.  Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.

Authors:  J A Kummer; A M Kamp; F Citarella; A J Horrevoets; C E Hack
Journal:  J Biol Chem       Date:  1996-04-19       Impact factor: 5.157

2.  Extracellular activities of human granzyme A. Monocyte activation by granzyme A versus alpha-thrombin.

Authors:  L E Sower; C J Froelich; N Allegretto; P M Rose; W D Hanna; G R Klimpel
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

3.  The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin.

Authors:  H S Suidan; K J Clemetson; M Brown-Luedi; S P Niclou; J M Clemetson; J Tschopp; D Monard
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

4.  IL-2 knockout recipient mice reject islet cell allografts.

Authors:  J Steiger; P W Nickerson; W Steurer; M Moscovitch-Lopatin; T B Strom
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

5.  The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection.

Authors:  T A Graubert; J H Russell; T J Ley
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

6.  Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.

Authors:  M Tewari; L T Quan; K O'Rourke; S Desnoyers; Z Zeng; D R Beidler; G G Poirier; G S Salvesen; V M Dixit
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

7.  Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells.

Authors:  S Shresta; D M MacIvor; J W Heusel; J H Russell; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

8.  Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B.

Authors:  A J Darmon; D W Nicholson; R C Bleackley
Journal:  Nature       Date:  1995-10-05       Impact factor: 49.962

9.  Granzyme A-deficient mice retain potent cell-mediated cytotoxicity.

Authors:  K Ebnet; M Hausmann; F Lehmann-Grube; A Müllbacher; M Kopf; M Lamers; M M Simon
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

10.  Granzyme A is an interleukin 1 beta-converting enzyme.

Authors:  M Irmler; S Hertig; H R MacDonald; R Sadoul; J D Becherer; A Proudfoot; R Solari; J Tschopp
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  69 in total

1.  Effects of gender on gene expression in the blood of ischemic stroke patients.

Authors:  Yingfang Tian; Boryana Stamova; Glen C Jickling; Dazhi Liu; Bradley P Ander; Cheryl Bushnell; Xinhua Zhan; Ryan R Davis; Piero Verro; William C Pevec; Nasim Hedayati; David L Dawson; Jane Khoury; Edward C Jauch; Arthur Pancioli; Joseph P Broderick; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

2.  Design Parameters for Granzyme-Mediated Cytotoxic Lymphocyte Target-Cell Killing and Specificity.

Authors:  Daniel J Woodsworth; Valentin Dunsing; Daniel Coombs
Journal:  Biophys J       Date:  2015-08-04       Impact factor: 4.033

3.  Alterations in RNA processing during immune-mediated programmed cell death.

Authors:  Danielle K Rajani; Michael Walch; Denis Martinvalet; Marshall P Thomas; Judy Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-15       Impact factor: 11.205

Review 4.  Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation.

Authors:  Sujatha Muralidharan; Pranoti Mandrekar
Journal:  J Leukoc Biol       Date:  2013-08-29       Impact factor: 4.962

5.  General Strategy for Direct Cytosolic Protein Delivery via Protein-Nanoparticle Co-engineering.

Authors:  Rubul Mout; Moumita Ray; Tristan Tay; Kanae Sasaki; Gulen Yesilbag Tonga; Vincent M Rotello
Journal:  ACS Nano       Date:  2017-06-15       Impact factor: 15.881

6.  Responses of the mammary transcriptome of dairy cows to altered photoperiod during late gestation.

Authors:  P A Bentley; E H Wall; G E Dahl; T B McFadden
Journal:  Physiol Genomics       Date:  2015-07-14       Impact factor: 3.107

7.  Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.

Authors:  Denis Comte; Maria P Karampetsou; Nobuya Yoshida; Katalin Kis-Toth; Vasileios C Kyttaris; George C Tsokos
Journal:  Arthritis Rheumatol       Date:  2017-05       Impact factor: 10.995

Review 8.  Harnessing CD4⁺ T cell responses in HIV vaccine development.

Authors:  Hendrik Streeck; M Patricia D'Souza; Dan R Littman; Shane Crotty
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

9.  Expression profile of microRNAs following bone marrow-derived mesenchymal stem cell treatment in lipopolysaccharide-induced acute lung injury.

Authors:  Joonhong Park; Sikyoung Jeong; Kicheol Park; Keumjin Yang; Soyoung Shin
Journal:  Exp Ther Med       Date:  2018-05-02       Impact factor: 2.447

10.  SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin.

Authors:  Jason Z Niehaus; Mark T Miedel; Misty Good; Allyson N Wyatt; Stephen C Pak; Gary A Silverman; Cliff J Luke
Journal:  Biochemistry       Date:  2015-11-05       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.